Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.

Moyle GJ, Orkin C, Fisher M, Dhar J, Anderson J, Wilkins E, Ewan J, Ebrahimi R, Wang H; ROCKET 1 (Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial) Study Group.

PLoS One. 2015 Feb 6;10(2):e0116297. doi: 10.1371/journal.pone.0116297. eCollection 2015.

2.

Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy.

Moyle GJ, Hardy H, Farajallah A, McGrath SJ, Kaplita S, Ward D.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):40-5. doi: 10.1097/QAI.0000000000000383.

PMID:
25296097
3.

Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.

Moyle GJ, Hardy H, Farajallah A, DeGrosky M, McGrath D.

Clin Drug Investig. 2014 Apr;34(4):287-96. doi: 10.1007/s40261-014-0175-4.

PMID:
24557728
4.

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.

Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H, Sedani S, Gartland M; ASSERT Team.

Antivir Ther. 2013;18(7):905-13. doi: 10.3851/IMP2667. Epub 2013 Jul 31.

PMID:
23899468
5.

Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy.

Herasimtschuk AA, Hansen BR, Langkilde A, Moyle GJ, Andersen O, Imami N.

Clin Exp Immunol. 2013 Sep;173(3):444-53. doi: 10.1111/cei.12141.

6.

A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.

Moyle GJ, Andrade-Villanueva J, Girard PM, Antinori A, Salvato P, Bogner JR, Hay P, Santos J, Astier L, Pans M, Balogh A, Biguenet S; ReAL Study Team.

Antivir Ther. 2012;17(4):689-700. doi: 10.3851/IMP2083. Epub 2012 Mar 2.

PMID:
22388634
7.

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.

Vrouenraets SM, Wit FW, Fernandez Garcia E, Moyle GJ, Jackson AG, Allavena C, Raffi F, Jayaweera DT, Mauss S, Katlama C, Fisher M, Slama L, Hardy WD, Dejesus E, van Eeden A, Reiss P; BASIC Study Group.

HIV Med. 2011 Nov;12(10):620-31. doi: 10.1111/j.1468-1293.2011.00941.x. Epub 2011 Aug 7.

PMID:
21819530
8.

Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.

Cooper V, Moyle GJ, Fisher M, Reilly G, Ewan J, Liu HC, Horne R; SWEET (Simplification With Easier Emtricitabine Tenofovir) group, UK.

AIDS Care. 2011 Jun;23(6):705-13. doi: 10.1080/09540121.2010.534433.

PMID:
21476152
9.

Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.

Randell PA, Jackson AG, Boffito M, Back DJ, Tjia JF, Taylor J, Mandalia S, Moyle GJ.

Antivir Ther. 2010;15(8):1125-32. doi: 10.3851/IMP1675.

PMID:
21149919
10.

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, Branco T, Pearce HC, Givens N, Vavro C, Lim ML.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):49-57. doi: 10.1097/QAI.0b013e3181dd911e.

PMID:
20431394
11.

The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.

Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ.

Antivir Ther. 2010;15(2):227-33. doi: 10.3851/IMP1518.

PMID:
20386078
12.

A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.

Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, Wilkins E, Ewan J, Liu H, Ebrahimi R, Reilly G; SWEET (Simplification With Easier Emtricitabine Tenofovir) group UK.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):562-8. doi: 10.1097/QAI.0b013e3181ae2eb9.

PMID:
19561519
13.

Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.

Ware LJ, Jackson AG, Wootton SA, Burdge GC, Morlese JF, Moyle GJ, Jackson AA, Gazzard BG.

Br J Nutr. 2009 Oct;102(7):1038-46. doi: 10.1017/S0007114509338817. Epub 2009 Jun 1.

PMID:
19480729
14.

Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.

Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ, Sax PE.

AIDS Read. 2009 Apr;19(4):158-60. No abstract available.

PMID:
19388184
15.

Antiretroviral therapy update from the 48th ICAAC/46th IDSA annual meeting.

Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ, Sax P.

AIDS Read. 2009 Jan;19(1):22-31. No abstract available.

PMID:
19209453
16.

Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up.

Herasimtschuk AA, Westrop SJ, Moyle GJ, Downey JS, Imami N.

J Immune Based Ther Vaccines. 2008 Oct 31;6:7. doi: 10.1186/1476-8518-6-7.

17.

Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone.

Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V, Higgins N, Grundy A, Moyle GJ.

HIV Clin Trials. 2008 Jul-Aug;9(4):254-68. doi: 10.1310/hct0904-254.

PMID:
18753120
18.

Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.

Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ; Epivir-Ziagen (EZ) Switch Study Team.

HIV Med. 2008 Oct;9(8):667-72. doi: 10.1111/j.1468-1293.2008.00618.x. Epub 2008 Jul 8.

PMID:
18631255
19.

Update on antiretroviral therapy: the 15th CROI.

Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ, Sax P.

AIDS Read. 2008 May;18(5):273-8, C3. Review. No abstract available.

PMID:
18589484
20.

Advances in HIV therapeutics: news from the 4th International AIDS Society Conference.

Boyle BA, Elion R, Cohen CJ, DeJesus E, Hawkins T, Moyle GJ.

AIDS Read. 2007 Oct;17(10):484-90. No abstract available.

PMID:
17990370
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk